Allogene Therapeutics Inc

Gesloten

SectorGezondheidszorg

2.12 3.92

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.07

Max

2.12

Belangrijke statistieken

By Trading Economics

Inkomsten

-3.8M

-43M

EPS

-0.18

Werknemers

150

EBITDA

-91K

-39M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+303.29% upside

Dividenden

By Acuity

Volgende Winsten

12 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-62M

725M

Vorige openingsprijs

-1.8

Vorige sluitingsprijs

2.12

Nieuwssentiment

By Acuity

50%

50%

110 / 342 Rangschikking in Healthcare

Allogene Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 jun 2026, 00:02 UTC

ETF Constituents
News

SPDR Dow Jones Industrial Average ETF Trust rises in after-market trading amid geopolitical tensions and mixed U.S. equity performance, supported by gains from major companies.

27 jun 2026, 00:02 UTC

Social Media
News

Fox Corp shares are lower in after-hours trading, amid discussions on FIFA World Cup viewership and a proposed merger raising regulatory concerns.

27 jun 2026, 00:02 UTC

News

Fox Corp shares are lower in after-market hours, reflecting a decline from Friday's close despite increased soccer viewership during the FIFA World Cup.

26 jun 2026, 23:51 UTC

News

iShares 20+ Year Treasury Bond ETF declines in after-market trading amid heightened geopolitical tensions from military actions in the Middle East.

26 jun 2026, 23:41 UTC

News

Charter Communications is in talks with SpaceX for a partnership to enhance mobile services using Starlink, with shares trading higher in after-market hours.

26 jun 2026, 23:31 UTC

Social Media
News

Barclays raised its price target for Micron Technology, citing strong earnings and AI demand. Shares are higher in after-market trading alongside broader market gains.

26 jun 2026, 23:26 UTC

Social Media
News
ETF Constituents

Invesco QQQ Trust gains in after-market trading as retail sentiment turns bullish, contrasting with declines in the broader market amid tech sell-off.

26 jun 2026, 23:16 UTC

Social Media
News

Amazon's stock rises after AWS announces a notable price increase in Nvidia compute services. Wells Fargo maintains a Buy rating and sets a target of $312.

26 jun 2026, 23:06 UTC

News

Amgen Inc shares declined in after-market trading following its revenue projections of $37.1 billion to $38.5 billion and significant debt of $57 billion.

26 jun 2026, 23:02 UTC

News
ETF Constituents

SPDR Dow Jones Industrial Average ETF Trust rises in after-market trading, supported by gains from top holdings and the Dow's third consecutive weekly increase.

26 jun 2026, 23:02 UTC

Social Media
ETF Constituents
News

SPDR S&P 500 ETF Trust rises in after-market trading following S&P's affirmation of U.S. sovereign ratings, reflecting positive economic growth expectations.

26 jun 2026, 23:02 UTC

Social Media
News

The United States Oil Fund LP rose after military strikes in the Strait of Hormuz heightened concerns over oil supply stability and increased trading activity.

26 jun 2026, 23:02 UTC

Social Media
News

Fox Corp shares are trading lower in after-market hours, despite strong preliminary viewership for the USA vs. Turkiye World Cup match and merger discussions.

26 jun 2026, 23:01 UTC

News

Fox Corp shares are lower in after-market trading amid broader market concerns over inflation and weakening momentum in AI-driven stocks, despite strong viewership for FIFA matches.

26 jun 2026, 20:15 UTC

News
Correlated Moves
ETF Constituents

Vanguard Large-Cap ETF trades lower in after-market hours, reflecting declines in major holdings and a drop in the S&P 500 Index.

26 jun 2026, 20:07 UTC

Correlated Moves
News
Macro Event

Bitcoin is higher today, reflecting a slight gain since Thursday's close. The Goods Trade Balance widened to a record deficit of $105.8 billion.

26 jun 2026, 20:07 UTC

Macro Event
News
Correlated Moves

Bitcoin is higher during Friday's session, reflecting a slight gain since Thursday. Broader market sentiment appears to influence both Bitcoin and Ethereum.

26 jun 2026, 20:06 UTC

Correlated Moves
News

The US dollar's decline pressures USD/SGD, which has traded lower since Thursday. Broader inflation concerns are influencing the asset's performance today.

26 jun 2026, 20:06 UTC

News

The USD/NOK is higher today, supported by recent currency market dynamics. The US dollar declines amid falling oil prices and weak technology shares.

26 jun 2026, 20:05 UTC

Social Media
News

Tesla Inc. shares are higher, supported by a report showing 15.78% revenue growth and strong EBITDA of $2.43 billion, exceeding industry averages.

26 jun 2026, 20:05 UTC

Social Media
News
Correlated Moves

Shares of Alphabet Inc. are trading lower amid concerns about Waymo's impact on competitors, as noted in a recent BTIG analysis.

26 jun 2026, 20:05 UTC

Social Media
News

Microsoft shares are higher amid a market rally, fueled by Michael Burry's bullish sentiment and a valuation surpassing $2.75 trillion.

26 jun 2026, 20:04 UTC

News

Bank of America Securities reiterated its Buy rating on Ulta Beauty, setting a price target of $685 after a meeting with company executives. Shares are higher today.

26 jun 2026, 20:03 UTC

News
Correlated Moves
Social Media

Intel Corp shares are declining as the semiconductor sector faces pressure. High trading volume reflects increased investor activity amid mixed social media sentiment.

26 jun 2026, 20:02 UTC

News
Correlated Moves
Social Media

Applied Materials Inc shares are lower amid a decline in the Semiconductor Materials & Equipment sector, despite recent price target increases from analysts.

26 jun 2026, 19:56 UTC

News
Correlated Moves

The U.S. goods trade deficit widened to $105.8 billion in May 2026, influencing economic perceptions. Vanguard Total Bond Market ETF is higher since Thursday's close.

26 jun 2026, 19:56 UTC

News
Correlated Moves

The U.S. goods trade deficit widened to $105.8 billion in May 2026, potentially impacting economic perceptions and Federal Reserve interest rate decisions.

26 jun 2026, 19:52 UTC

Correlated Moves
News
Social Media

Broadcom Inc shares fell to $370.12, a 10-week low, amid a broader downturn in the semiconductor sector and negative investor sentiment.

26 jun 2026, 19:52 UTC

Social Media
News

Qualcomm Inc's stock is lower amid concerns over competition and supply shortages following its new chip architecture announcements for smartphones and data centers.

26 jun 2026, 19:52 UTC

Social Media
News
Correlated Moves

NVIDIA Corp shares are declining as Amazon Web Services raises GPU prices, potentially reducing demand. Market focus shifts to memory stocks amid broader pressures.

Peer Vergelijking

Prijswijziging

Allogene Therapeutics Inc Prognose

Koersdoel

By TipRanks

303.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8.59 USD  303.29%

Hoogste 14 USD

Laagste 3.85 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Allogene Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Sentiment

By Acuity

110 / 342 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat